CP - KCS Deal Looking Certain

Sep 14, 2021

It almost seems certain now, that Calgary based CP rail will move forward in acquiring Kansas City Southern.

On the weekend, the board at KC said the bid of about 31 billion dollars by CP, which includes debt was superior to the offer being made by rival CN. Initially, the company had accepted CP's bid, months ago, but then entertained a sweeter off by CN. But it was dealt a major setback recently when the US surface transportation board rejected CN's use of a voting trust to complete the deal.

CP said on the weekend, its merger with KCS would maintain all existing freight rail gateways while creating new north-south lanes between western Canada, the US, upper Midwest, the gulf coast and Mexico. CP also said the deal would create a route network that doesn't funnel all of its traffic through the already congested Chicago area.

Meanwhile, some of the top shareholders for CN are demanding changes to the current board of directors and the firing of the company's CEO.

Click here to see more...

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.